BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium

NEXT STORY
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
PREV STORY
Hematuria Treatment Market Size ($1,103.61Mn by 2028) Led by Urinary Tract Infections (17.31% Market Share in 2020) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium

author_avatar
NASDAQ Market News

Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece

author_avatar
NASDAQ Market News

BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis

author_avatar
NASDAQ Market News